• About
  • Meet The Team
  • Privacy Policy
Sunday, February 28, 2021

Stocks Telegraph
  • Login
  • Home
  • Featured
  • Investing
  • Morning News
  • Mid Day Movers
No Result
View All Result
Stocks Telegraph
No Result
View All Result

TRACON Pharmaceuticals (NASDAQ: TCON) Receives FDA TRC102 Orphan Drug Designation

by Hasnain R
October 26, 2020
in Featured, Mid Day Movers
Share on FacebookShare on Twitter

TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) has announced today that it has received Orphan Drug Designation for TRC102 for the treatment of patients suffering from malignant Glioma and glioblastoma (GBM) from the US Food and Drug Administration (FDA). In the Orphan Drug Designation, the drug has been given the Orphan status. This status is given to the companies to provide them with financial benefits for the development of new drugs for the treatment of rare diseases.

TRC102 is being examined in Phase 1 and Phase 2 clinical trials which were sponsored by the National Cancer Institute through a Cooperative Research and Development Agreement (CRADA). In Phase II, TRC102 was analyzed with Temodar chemotherapy. This study has been done on 19 patients who were suffering from progressive or recurrent GBM.

Thes study has shown promising results and increase the time of survival in two patients for more than two years. Both patients have shown the activation of the DNA base excision repair pathway and shown hyperactivation of DNA damage response genes.

Furthermore, TRC102 has also been analyzed in combination with chemotherapy and external beam radiotherapy in a Phase 1 study. 15 patients have participated in this study who have newly diagnosed non-squamous cell non-small cell lung cancer.

TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) shares were trading up 9.29% at $4.94 during the trading session of Friday. TRACON Pharmaceuticals, Inc. (TCON) share price went from a low point around $0.95 to briefly over $6.37 in the past 52 weeks. It has traded up 420.00% from its 52-weeks low and moved down -22.45% from its 52-weeks high. TCON market cap has remained high, hitting $59.58 million at the time of writing.

Orphan Drug Designation status for TRC102 will be helpful in providing the treatment for unmet medical needs of patients who are suffering from malignant glioma. TRACON Pharmaceuticals has committed to developing TRC102 with the help of the National Cancer Institute.

Get The Best Stocks To Trade Every Day!

Join now to get the Stockstelegraph.com pre-market morning brief 100% free

Tags: FDAglioblastomaMalignant GliomaNASDAQ: TCONNational Cancer InstituteOrphan Drug DesignationTCON stockTRACON Pharmaceuticals Inc.

Related Posts

ASML Holding (NASDAQ: ASML) Announces 2020 Q3 Results
Featured

What dragged Vistra Corp (VST) about 25% lower?

February 27, 2021
High Flying Plasma Pharmaceuticals as FDA Approves Plasma-based COVID-19 Treatment
Featured

Three Top Coronavirus Stocks to Buy Anytime Soon

February 27, 2021
Tesla Inc. (NASDAQ: TSLA) Reportedly Discuss Nickel Supply Deal With Top Miner BHP
Featured

AMC Entertainment (AMC) Avoids Bankruptcy as Shares Pop Up

January 27, 2021
Top 3 Health Care Stocks that can attract investors in 2021
Featured

Top 3 Health Care Stocks that can attract investors in 2021

January 27, 2021
Sunworks (NASDAQ: SUNW) Stock Is Soaring Today. Here’s Why
Featured

Overstock.com (OSTK) Set to Convert its blockchain-based subsidiary to a limited partnership “Fund”

January 27, 2021
Top 15 Best Performing Medical Device Manufacture Companies Of 2020
Featured

3 Best Communication Stocks to Buy this year

January 26, 2021
Next Post
12 Trending Stocks In Mining Industry To Watch

7 Trending Stocks In Specialty Industrial Machinery Industry

GameStop Corp. (GME) Stock has skyrocketed in the Pre-Market: What’s happening?

Top 3 Reasons Why AzurRx Biopharma Inc [AZRX] is Gaining Bullish Momentum
by ST Staff
February 25, 2021
0

GameStop Corp. (GME) shares have been on a skywalk. The videogame platform seller is captivating the attention in the market...

Read more

Early Morning Vibes: 4 Stocks We Like for Monday…

GEVO Inc [GEVO]  – A Top Stock To Watch For The Remainder Of 2020
by Hasnain R
February 22, 2021
0

The American stock markets could not be fired ahead last week. The results were limited and as you can see...

Read more

ReTo Eco-Solutions (RETO) Shares are Jumping High, What’s Happening?

Top Gainers as Positive Market Sentiment Grows
by Ali Hassan
February 23, 2021
0

The shares of ReTo are on a roll, probably on a bullish response from investors regarding some rumors. The shares...

Read more

The Three Best Hydrogen Stocks to Watch For in 2021

The Three Best Hydrogen Stocks to Watch For in 2021
by Ali Hassan
February 24, 2021
0

Hydrogen technology is the next big thing that is part of the Go Green movement. In the recent few months,...

Read more

Early Morning Vibes: 4 Top Trending Stocks To Watch Right Now

GEVO Inc [GEVO]  – A Top Stock To Watch For The Remainder Of 2020
by Hasnain R
February 23, 2021
0

US stock exchanges fell on Monday in line with the overall decline in risk sentiment in global markets, according to...

Read more
  • About
  • Meet The Team
  • Privacy Policy

© 2020 Stocks Telegraph - All Rights Reserved

No Result
View All Result
  • Home
  • Featured
  • Investing
  • Morning News
  • Mid Day Movers

© 2020 Stocks Telegraph - All Rights Reserved

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Get The Best Stocks To Trade Every Day!

Join now to get the Stockstelegraph.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.